EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Early Safety Results from the Phase 3b SIERRA Study of Durvalumab and Tremelimumab as First-Line Treatment for Participants with Unresectable Hepatocellular Carcinoma and a Poor Prognosis

Stephen Lam Chan, Masatoshi Kudo, Bruno Sangro, Robin Kate Kelley, Jee Hyun Kim, Binh Pham, Jung Yong Hong, Dirk-Thomas Waldschmidt, Donatella Marino, Jie Xin Joycelyn Lee, René Gerolami, Adam M Burgoyne und 5 weitere

Liver Cancer · 18.12.2025 · 1-11

DOI: 10.1159/000549955 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver Cancer, online erschienen am 18.12.2025. Verfasst von Stephen Lam Chan und 16 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Translational Oncology, Department of Clinical Oncology, Sir Yue-Kong Pao Center for Cancer, Prince of Wales Hospital, The Ch…. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Subgroups of people with unresectable hepatocellular carcinoma (uHCC) are often excluded from clinical trials due to adverse prognostic factors. The SIERRA (NCT05883644) study assesses the efficacy and safety of STRIDE (Single Tremelimumab Regular Interval Durvalumab) in clinically relevant subgroups of uHCC with poorer prognosis, including participants with more decompensated hepatic function, worse performance status, or more advanced disease than the HIMALAYA (NCT03298451) study.

Methods

SIERRA is a phase 3b, single-arm, multicenter study that enrolled participants with uHCC with: Child-Pugh (CP) class of B7 or B8 with Eastern Cooperative Oncology Group performance status (ECOG PS) 0–1, without main trunk portal vein thrombosis (PVT) (CP B7/B8 cohort); CP class A with ECOG PS 2, without main trunk PVT (ECOG PS 2 cohort); or CP class A with ECOG PS 0–1 with evidence of chronic main trunk PVT (Vp4 cohort). Participants received STRIDE (tremelimumab 300 mg plus durvalumab 1,500 mg once followed by durvalumab 1,500 mg every 4 weeks). This preplanned early safety analysis occurred once ∼60 participants had been followed for ≥6 months (data cutoff: September 27, 2024). Co-primary endpoints are incidence of grade 3/4 adverse events (AEs) possibly related to study treatment (PRAEs) within 6 months of treatment initiation and objective response rate. The study is ongoing.

Results

This analysis included 98 participants (CP B7/B8 cohort, n = 35; ECOG PS 2 cohort, n = 44; Vp4 cohort, n = 19). Median (Q1–Q3) number of cycles of durvalumab was 4.0 (2.0–8.0). Incidence of grade 3/4 PRAEs occurring within 6 months of treatment was 19.4% (95% confidence interval, 12.1–28.6) overall. Incidence of serious AEs was 32.7%. PRAEs, leading to death, occurred in 2.0% of participants.

Conclusion

The safety profile of STRIDE was manageable and consistent with the HIMALAYA study in participants with poorer prognosis than in HIMALAYA.

Schlagwörter

Stichwörter der Autor:innen

CirrhosisCombinationImmunotherapyLiver neoplasmSafetyVascular invasion

Autor:innen und Institutionen

  • State Key Laboratory of Translational Oncology, Department of Clinical Oncology, Sir Yue-Kong Pao Center for Cancer, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR.
  • Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.
  • Liver Unit and HPB Oncology Area, Clínica Universidad de Navarra and CIBEREHD, Pamplona, Spain.
  • Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.
  • Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea.
  • Abdominal Department 1 and Robotic Surgery, Vietnam National Cancer Hospital, Hanoi, Vietnam.

Zitieren

APA

Chan, S. L., Kudo, M., Sangro, B., Kelley, R. K., Kim, J. H., Pham, B., Hong, J. Y., Waldschmidt, D. T., Marino, D., Joycelyn Lee, J. X., Gerolami, R., Burgoyne, A. M., Li, Q., Nakamura, H., Sun, P., Baur, B., & Rimassa, L. (2025). Early Safety Results from the Phase 3b SIERRA Study of Durvalumab and Tremelimumab as First-Line Treatment for Participants with Unresectable Hepatocellular Carcinoma and a Poor Prognosis. Liver Cancer, 1-11. https://doi.org/10.1159/000549955

Vancouver

Chan SL, Kudo M, Sangro B, Kelley RK, Kim JH, Pham B, et al. Early Safety Results from the Phase 3b SIERRA Study of Durvalumab and Tremelimumab as First-Line Treatment for Participants with Unresectable Hepatocellular Carcinoma and a Poor Prognosis. Liver Cancer. 2025:1-11. doi:10.1159/000549955

BibTeX
@article{Chan2025,
  author = {Chan, Stephen Lam and Kudo, Masatoshi and Sangro, Bruno and Kelley, Robin Kate and Kim, Jee Hyun and Pham, Binh and Hong, Jung Yong and Waldschmidt, Dirk-Thomas and Marino, Donatella and Joycelyn Lee, Jie Xin and Gerolami, René and Burgoyne, Adam M and Li, Qiao and Nakamura, Hitomi and Sun, Peng and Baur, Boris and Rimassa, Lorenza},
  title = {Early Safety Results from the Phase 3b SIERRA Study of Durvalumab and Tremelimumab as First-Line Treatment for Participants with Unresectable Hepatocellular Carcinoma and a Poor Prognosis},
  journal = {Liver Cancer},
  year = {2025},
  pages = {1--11},
  doi = {10.1159/000549955}
}
Kostenlos starten →